Biocept BRAF Liquid Biopsy Test
Biocept has launched a blood-based BRAF mutation test to help physicians identify melanoma patients who might benefit from currently available targeted therapies. According to the company, because of the high sensitivity of the assay, it could also be used to monitor patients' response to treatment and the progression of disease during the course of therapy.
A quantitative assay, the BRAF test joins Biocept's existing portfolio of liquid biopsy tests for breast, lung and gastric cancer biomarkers. The firm's platform analyzes circulating tumor DNA in circulating tumor cells and plasma.